<DOC>
	<DOCNO>NCT02933580</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics ( PK ) JNJ-56136379 healthy Japanese adult participant follow oral administration single dose 25 milligram ( mg ) 600 mg , fasted condition .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-56136379 Healthy Japanese Adult Participants</brief_title>
	<detailed_description />
	<criteria>Participant must Japanese participant reside outside Japan 10 year whose parent grandparents Japanese determine participant 's verbal report Participant must healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical surgical history , vital sign , result blood biochemistry , blood coagulation , hematology test urinalysis perform screening . If abnormality , participant may include investigator judge abnormality clinically significant appropriate reasonable population study . This determination must record participant 's source document initialed/signed investigator Participant must body mass index ( BMI ; weight kilogram [ kg ] divide square height meter ) 18.0 30.0 kilogram per meter square [ kg/m^2 ] , extremes inclusive , body weight less 45.0 kg Participant must normal 12lead electrocardiogram ( ECG ) ( base mean value triplicate parameter ) screen include : normal sinus rhythm ( heart rate 45 100 beat per minute [ bpm ] , extremes include ) ; QT interval correct heart rate accord Fridericia ( QTcF ) less equal ( &lt; = ) 450 millisecond ( m ) ; QRS interval le ( &lt; ) 120 m ; PR interval &lt; =220 ms A female participant ( except permanently sterile ) , negative serum pregnancy test screen female participant negative urine pregnancy test Day 1 Participant past history cardiac arrhythmia ( example [ eg ] , extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Female participant breastfeed screen pregnant screen predose Male participant plan father child enrol study within 90 day study drug administration Participant current human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection ( confirmed antibody ) Screening Participant current hepatitis A infection ( confirm hepatitis A antibody immunoglobulin M [ IgM ] ) , hepatitis B virus ( HBV ) infection ( confirm HBsAg ) , hepatitis C virus ( HCV ) infection ( confirm HCV antibody ) , hepatitis E infection ( confirm hepatitis E antibody IgM ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>